Ziyu Xun

942 total citations · 1 hit paper
35 papers, 340 citations indexed

About

Ziyu Xun is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ziyu Xun has authored 35 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 15 papers in Surgery and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ziyu Xun's work include Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers), Hepatocellular Carcinoma Treatment and Prognosis (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Ziyu Xun is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers), Hepatocellular Carcinoma Treatment and Prognosis (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Ziyu Xun collaborates with scholars based in China, United Kingdom and United States. Ziyu Xun's co-authors include Haitao Zhao, Xiaobo Yang, Xinting Sang, Junyu Long, Nan Zhang, Yanyu Wang, Longhao Zhang, Dongxu Wang, Jiashuo Chao and Yunchao Wang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Ziyu Xun

33 papers receiving 339 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma

2024 43 citations Nan Zhang, Yang Xu et al. Biomarker Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ziyu Xun China	11	175	114	112	94	72	35	340
Maria Aurelia Barbera Italy	9	134 0.8×	80 0.7×	104 0.9×	70 0.7×	69 1.0×	19	284
Juxiang Xiao China	10	275 1.6×	107 0.9×	163 1.5×	157 1.7×	47 0.7×	14	440
Yanfu Sun China	10	106 0.6×	152 1.3×	144 1.3×	121 1.3×	87 1.2×	15	367
Wen‐Ping Lin China	13	196 1.1×	60 0.5×	185 1.7×	90 1.0×	65 0.9×	30	388
Quanren Wang China	1	245 1.4×	61 0.5×	131 1.2×	148 1.6×	49 0.7×	2	368
Songqiang Zhou China	9	107 0.6×	74 0.6×	178 1.6×	82 0.9×	34 0.5×	15	294
Dalu Kong China	12	138 0.8×	93 0.8×	131 1.2×	70 0.7×	129 1.8×	33	414
Youen Lin China	4	87 0.5×	89 0.8×	193 1.7×	60 0.6×	37 0.5×	6	284
Zhong-Guo Zhou China	11	196 1.1×	78 0.7×	147 1.3×	77 0.8×	62 0.9×	17	387
Qiaoqi Sui China	11	215 1.2×	86 0.8×	48 0.4×	63 0.7×	42 0.6×	21	288

Countries citing papers authored by Ziyu Xun

Since Specialization

Citations

This map shows the geographic impact of Ziyu Xun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ziyu Xun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ziyu Xun more than expected).

Fields of papers citing papers by Ziyu Xun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ziyu Xun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ziyu Xun. The network helps show where Ziyu Xun may publish in the future.

Co-authorship network of co-authors of Ziyu Xun

This figure shows the co-authorship network connecting the top 25 collaborators of Ziyu Xun. A scholar is included among the top collaborators of Ziyu Xun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ziyu Xun. Ziyu Xun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Chengjie, Yang Xu, Shuofeng Li, et al.. (2025). Conversion Surgery after Immune Checkpoint Inhibitor-Based Combination Therapy for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study. Liver Cancer. 14(4). 456–473. 1 indexed citations

Chao, Jiashuo, Yuan Liang, Hao Wang, et al.. (2025). FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma. Nature Communications. 16(1). 9547–9547.

Xun, Ziyu, Nan Zhang, Chengjie Li, et al.. (2025). Single-cell transcriptomic analysis deciphers the inflammatory microenvironment characterized by CXCL9+ fibroblasts and ACKR1+ endothelial cells in immune-related myocarditis. Journal of Translational Medicine. 23(1). 555–555. 1 indexed citations

Li, Shuofeng, Guanhua Yu, Mingming Wang, et al.. (2025). Local–regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study. Cancer Immunology Immunotherapy. 74(8). 271–271.

Chao, Jiashuo, Hao Wang, Shuofeng Li, et al.. (2024). Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study. Cancer Immunology Immunotherapy. 73(12). 249–249. 3 indexed citations

Li, Zhaohui, Yutao Liu, Di Shi, et al.. (2024). Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics. Hepatology International. 18(6). 1770–1780. 6 indexed citations

Zhang, Chenchen, Shanshan Wang, Ziyu Xun, et al.. (2024). Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 12(6). e008686–e008686. 19 indexed citations

Zhang, Ting, Chengpei Zhu, Nan Zhang, et al.. (2024). Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer. International Immunopharmacology. 129. 111642–111642. 7 indexed citations

Zhang, Nan, Yang Xu, Ziyu Xun, et al.. (2024). Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomarker Research. 12(1). 26–26. 43 indexed citations breakdown →

10.

Xun, Ziyu, Junyu Long, Xu Yang, et al.. (2024). Immunosuppression and phenotypic plasticity in an atlas of human hepatocholangiocarcinoma. HepatoBiliary Surgery and Nutrition. 13(4). 586–603. 2 indexed citations

11.

Xun, Ziyu, et al.. (2023). Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade. Cancer Cell International. 23(1). 313–313. 13 indexed citations

12.

Zhang, Longhao, Jingnan Xue, Nan Zhang, et al.. (2023). The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.. PubMed. 13(8). 3582–3590. 2 indexed citations

13.

Wang, Yanyu, Xu Yang, Junyu Long, et al.. (2023). Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. World Journal of Gastroenterology. 29(10). 1614–1626. 21 indexed citations

14.

Xun, Ziyu, et al.. (2023). Development and validation of a genomic instability-related lncRNA prognostic model for hepatocellular carcinoma. Frontiers in Genetics. 13. 1034979–1034979. 2 indexed citations

15.

Huang, Bowen, Jianzhou Liu, Jun Lü, et al.. (2022). Aerial View of the Association Between m6A-Related LncRNAs and Clinicopathological Characteristics of Pancreatic Cancer. Frontiers in Oncology. 11. 812785–812785. 7 indexed citations

16.

Long, Junyu, Yiran Li, Fucun Xie, et al.. (2022). Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma. Frontiers in Cell and Developmental Biology. 10. 910749–910749. 2 indexed citations

17.

Yang, Xiaobo, Longhao Zhang, Jingnan Xue, et al.. (2022). High incidence combination of multiple primary malignant tumors of the digestive system. World Journal of Gastroenterology. 28(41). 5982–5992. 14 indexed citations

18.

Chen, Bowen, Yanyu Wang, Yunchao Wang, et al.. (2022). Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers.. Journal of Clinical Oncology. 40(16_suppl). e16155–e16155. 1 indexed citations

19.

Yang, Xiaobo, Haifeng Xu, Yang Xu, et al.. (2021). Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. HepatoBiliary Surgery and Nutrition. 10(4). 434–442. 37 indexed citations

20.

Wang, Dongxu, Xu Yang, Junyu Long, et al.. (2021). The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study. Frontiers in Oncology. 11. 646979–646979. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact